Cellectar Biosciences Announced Preclinical Data For Its Proprietary Novel Alpha-emitting Phospholipid Radiotherapeutic Conjugate, CLR 121225, An Actinium-labeled Phospholipid Ether, In Pancreatic Cancer Models

Author: Benzinga Newsdesk | January 16, 2024 07:41am

In preclinical studies, CLR 121225 demonstrated potent anti-tumor activity in refractory pancreatic cancer mouse xenograft models. A single administration at each dose level (100nCi, 250nCi and 500nCi) resulted in tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor. Additionally, it was shown that CLR 121225 demonstrated excellent biodistribution; approximately 15 – 20% of the infused drug accumulated in the tumor within four hours and continued to accumulate over 72 – 96 hours. The mice had no end organ toxicities demonstrating good tolerability. The data are consistent with experiments using other alpha emitters conjugated to the company's proprietary PLE targeted delivery platform.

Posted In: CLRB